Skip to main content
. Author manuscript; available in PMC: 2022 Feb 5.
Published in final edited form as: Arch Pathol Lab Med. 2021 Aug 1;145(8):960–968. doi: 10.5858/arpa.2020-0322-OA

Table 4.

Neuropathology Results, Massachusetts Alzheimer’s Disease Research Center (MADRC; 19) Versus Simplified (6)a

Case Premortem Clinical Diagnosis 19 ADNC 6 ADNC 19 LBD Bk 6 LBD Bk 19 CAA 6 CAA 19 AS 6 AS 19 Other 6 Other
1 AD H H 0 0 2 2 2 2 Mic-inf None
2 AD H H 0 0 0 0 0 0 HS-TDP43 HS-TDP43b
3 AD H H 5 5 1 2 3 3 Mic-inf None
4 AD H H AD-rel AD-rel 2 3 3 3 TDP43pr TDP43prb
5 AD H H 0 0 0 0 1 1 None None
6 AD H H 0 0 2 2 2 2 None None
7 AD H H 0 0 3 3 3 3 AHI AHI
8 AD H H AD-rel AD-rel 3 3 2 2 None None
9 AD H H 0 0 1 1 2 1 None None
10 AD i L 0 0 2 2 2 2 TDP43pr None
11 AD, Presenilin-1 mutant H H 0 0 2 1 1 1 None None
12 AD (PCA) H H 5 5 3 3 0 0 TDP43pr TDP43prb
13 AD versus NPH H H 0 0 1 2 2 2 Mic-inf None
14 AD, early onset H H 5 5 2 2 2 2 None None
15 AD, ?lvPPA H H AD-rel 0 3 3 2 2 TDP43pr TDP43prb
16 AD versus FTD i i 6 6 0 0 0 0 TDP43pr None
17 Dementia, unclear etiology H H 5 3 2 2 3 3 TDP43pr TDP43prb
18 Mixed dementia H H 0 0 0 0 3 3 TDP43pr TDP43prb
19 Mixed dementia with CAA H H AD-rel 0 0 0 2 2 AHI AHI
20 AD with component of parkinsonism L L 5 4 0 0 2 2 None None
21 Dementia, ?PD L L 5 5 2 2 3 3 TDP43pr TDP43prb, Mic-inf
22 CAA H H 0 0 3 3 2 2 None None
23 CAA L L 0 0 4 4 3 3 AHI AHI
24 MCI, ?CBS, ?FTLD 0 0 0 0 0 0 2 2 None None
25 MCI i i 0 0 2 2 1 1 None None
26 MCI H H AD-rel AD-rel 2 2 2 2 TDP43pr TDP43prb
27 CBS versus PD versus DLB versus AD versus mixed L L 5 5 2 2 1 1 AHI AHI
28 PD i i 6 5 1 1 2 2 AHI, Mic-inf AHI
29 PD 0 0 5 4 0 0 2 2 None None
30 PD 0 0 3 3 0 0 3 3 PART PART
31 PD i L 4 4 0 0 3 3 TDP43pr TDP43prb
32 PD L L 5 5 0 0 1 1 None None
33 PDD L L 5 5 0 0 1 1 AHI None
34 DLB H H 5 5 0 0 2 2 None None
35 FTD with component of CBS H H 0 0 0 0 1 1 None None
36 FTD, known GRN mutation L L 0 0 0 0 0 0 FTLD-TDP, AHI FTLD-TDPb, AHI
37 FTD 0 0 0 0 0 0 1 1 CBD CBD
38 FTD 0 0 0 0 0 0 1 1 FTLD-TDP FTLD-TDPb, AHI
39 svPPA 0 0 0 0 0 0 1 1 FTLD-TDP, AHI FTLD-TDPb, AHI
40 lvPPA H H 0 0 0 0 3 2 None None
41 lvPPA H H AD-rel AD-rel 2 2 1 1 None None
42 navPPA H H 0 0 0 0 1 1 PSP PSP
43 navPPA, ?PSP L L 0 0 0 0 3 2 PSP PSP
44 PSP L L 0 0 0 0 1 1 PSP PSP
45 PSP 0 0 0 0 0 0 1 1 PSP PSP
46 MSA-P 0 0 0 0 0 0 2 1 MSA MSA
47 MSA-C 0 0 0 0 0 0 1 1 MSA MSA
48 Control; ?Mixed dementia L L 5 4 2 2 2 1 AHI AHI
49 Control L L 0 0 0 0 2 2 AHI AHI
50 Control L L 0 0 0 0 3 2 AHI Mic-inf
51 Control H H 5 5 3 3 3 2 TDP43pr TDP43prb
52 Control L L 0 0 0 0 1 1 Mic-inf Mic-inf

Abbreviations: ADNC, Alzheimer disease neuropathologic changes (scores: H, high; i, intermediate; L, low; 0, not); AD-rel, Alzheimer disease–related Lewy bodies; AHI, acute hypoxic/ischemic injury; AS, arteriolosclerosis (grades: 1, mild; 2, moderate; 3, severe); CAA, cerebral amyloid angiopathy (Vonsattel grades 0–4); CBD, corticobasal degeneration; CBS, corticobasal syndrome; FTD, frontotemporal dementia; FTLD, frontotemporal lobar degeneration; LBD Bk, Lewy body disease Braak staging (Braak stages 0–6); lvPPA, logopenic variant primary progressive aphasia; MCI, mild cognitive impairment; Mic-inf, microinfarct; MSA, multiple system atrophy; navPPA, nonfluent/agrammatic variant primary progressive aphasia; PART, primary age-related tauopathy; PSP, progressive supranuclear palsy; TDP43pr, TDP43-related proteinopathy; Unk, unknown.

a

Neuropathology results from the MADRC protocol (19) compared with the simplified protocol (6). Differences between the 2 protocols are italicized.

b

TDP43 immunohistochemistry done retrospectively (see Table 3 key for the clinical diagnosis acronyms).